Ohio physicians now have another reason to be familiar with and utilize the Ohio Automated Rx Reporting System (“OARRS”) as a component of their practices. While OARRS checks have been mandatory under certain circumstances since late 2011, the Ohio State Board of Pharmacy has just released information concerning a new OARRS feature, which stands to further enhance medication utilization review, monitoring and compliance. Since late 2006, information on prescriptions classified as Schedule II-V Controlled Substances, Carisoprodol and Tramadol has been collected and made available to practitioners and regulators through the OARRS prescription monitoring program. The Pharmacy Board has added a new feature to OARRS – the Practice Insight Report – to further aid Ohio health care providers.
The Practice Insight Report features the following information:
A list of the prescriber’s patients who are obtaining OARRS reportable medication from other providers. Such information may be emblematic of “doctor shopping” and other aberrant patient behavior.
A list of the prescriber’s patients that have the highest Morphine Equivalent Doses (“MED”). Please note that within the last year, the Ohio Boards of Medicine, Pharmacy, Dentistry, and Nursing have adopted new guidelines pertaining to evaluation and reevaluation of the efficacy and safety of a patient’s treatment plan upon reaching a daily level of 80 milligrams MED.1
A list of medications more frequently prescribed by the health care provider.
A list of patients that have received Schedule II-V Controlled Substances, Carisoprodol and Tramadol within the past 12 months.
The Pharmacy Board has stated that additional improvements to the Practice Insight Report will be forthcoming as new sources of information become available to the OARRS system.
To obtain the Practice Insight Report, an appropriately registered prescriber simply must log into the OARRS system, and select “practitioner” rather than the typical “patient” request icon. Within minutes, the provider will be armed with insightful information that can identify at-risk patients, point out conformity or deviation with MED guidelines, and reveal prescribing trends for the practitioner. Indeed, practitioners who make use of this new tool should see enhancements in prescribing practices, and minimize or avoid regulatory scrutiny. In addition, medical practices and their practitioners stand to enhance overall practice improvement in the utilization of such reports through applicable compliance programs, peer review committees, or by other means.
(1) For further information, please see prior Dinsmore Alert regarding Morphine Equivalent Dose: Ohio’s New Tool against Prescription Drug Abuse, issued November 12, 2013.